IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
Main Authors: | Etienne Dufranc, Arnaud Del Bello, Julie Belliere, Nassim Kamar, Stanislas Faguer, on behalf of the TAIDI (Toulouse Acquired Immune Deficiency and Infection) study group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | Critical Care |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13054-020-02878-7 |
Similar Items
-
Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study
by: Ju Yeon Kim, et al.
Published: (2022-09-01) -
Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report
by: Birgitte Tholin, et al.
Published: (2020-10-01) -
Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report
by: Ahmet Eroglu, et al.
Published: (2021-01-01) -
Hemophagocytic lymphohistiocytosis secondary to dengue fever
by: Simon Kashfi, et al.
Published: (2025-02-01) -
Deciphering the clinical profile and diagnostic framework of hemophagocytic lymphohistiocytosis in a tertiary care setting
by: Lipsa Priyadarshini, et al.
Published: (2024-12-01)